These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Why are pharmaceutical companies gradually abandoning vaccines? Offit PA Health Aff (Millwood); 2005; 24(3):622-30. PubMed ID: 15886152 [TBL] [Abstract][Full Text] [Related]
5. Vaccine supply: a cross-national perspective. Danzon PM; Pereira NS; Tejwani SS Health Aff (Millwood); 2005; 24(3):706-17. PubMed ID: 15886165 [TBL] [Abstract][Full Text] [Related]
6. The United States pediatric vaccine stockpile program. Lane KS; Chu SY; Santoli JM Clin Infect Dis; 2006 Mar; 42 Suppl 3():S125-9. PubMed ID: 16447134 [TBL] [Abstract][Full Text] [Related]
7. Vaccine manufacturing: challenges and solutions. Ulmer JB; Valley U; Rappuoli R Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488 [TBL] [Abstract][Full Text] [Related]
8. Vaccine supply problems: a perspective of the Centers for Disease Control and Prevention. Rodewald LE; Orenstein WA; Mason DD; Cochi SL Clin Infect Dis; 2006 Mar; 42 Suppl 3():S104-10. PubMed ID: 16447130 [TBL] [Abstract][Full Text] [Related]
9. Protecting the nation's health: ensuring a stable supply of influenza vaccine. Seiguer E Issue Brief (Commonw Fund); 2005 Jul; (832):1-14. PubMed ID: 16193600 [TBL] [Abstract][Full Text] [Related]
10. The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Jadhav S; Datla M; Kreeftenberg H; Hendriks J Vaccine; 2008 Mar; 26(13):1611-5. PubMed ID: 18294742 [TBL] [Abstract][Full Text] [Related]
11. Why sole-supplier vaccine markets may be here to stay. Danzon P; Pereira NS Health Aff (Millwood); 2005; 24(3):694-6. PubMed ID: 15886161 [TBL] [Abstract][Full Text] [Related]
12. Improving vaccine supply and development: who needs what? Pauly MV Health Aff (Millwood); 2005; 24(3):680-9. PubMed ID: 15886159 [TBL] [Abstract][Full Text] [Related]
14. The fragility of the U.S. vaccine supply. Sloan FA; Berman S; Rosenbaum S; Chalk RA; Giffin RB N Engl J Med; 2004 Dec; 351(23):2443-7. PubMed ID: 15575064 [No Abstract] [Full Text] [Related]
15. Encouraging the development of new vaccines. Grabowski H Health Aff (Millwood); 2005; 24(3):697-700. PubMed ID: 15886162 [TBL] [Abstract][Full Text] [Related]
16. The pediatric vaccine stockpiling problem. Truong VA Vaccine; 2012 Sep; 30(43):6175-9. PubMed ID: 22874852 [TBL] [Abstract][Full Text] [Related]
17. Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries. Batson A; Meheus F; Brooke S Vaccine; 2006 Aug; 24 Suppl 3():S3/219-25. PubMed ID: 16950010 [TBL] [Abstract][Full Text] [Related]
18. The role of emerging manufacturers in access to innovative vaccines of public health importance. Milstien JB; Kaddar M Vaccine; 2010 Feb; 28(9):2115-21. PubMed ID: 20044054 [TBL] [Abstract][Full Text] [Related]
19. Strengthening the supply of routinely administered vaccines in the United States: problems and proposed solutions. Klein JO; Myers MG Clin Infect Dis; 2006 Mar; 42 Suppl 3():S97-103. PubMed ID: 16447139 [TBL] [Abstract][Full Text] [Related]
20. The U.S. vaccine supply. Schwartz HK N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15762001 [No Abstract] [Full Text] [Related] [Next] [New Search]